A Dose Escalation Study of Long-acting ACTH Gel in Membranous Nephropathy

Status Completed

Clinical Trial Summary

Membranous Nephropathy (MN) is an immune-mediated kidney disease that affects the glomerulus or the filter that removes toxins from the blood. Damage to the membrane that separates blood from urine results in loss of protein into the urine (proteinuria) and in some cases loss of kidney function.There is no standard specific treatment for MN.

ACTH has a pronounced lipid-lowering effect in healthy individuals, in steroid-treated patients with renal disease and in hemodialysis patients Some studies suggest that prolonged synthetic ACTH therapy may represent an effective therapy in patients with idiopathic MN, more extensive randomized studies with longer follow-up are needed before therapeutic recommendations can be made.

We propose to do a pilot study to test the hypothesis that biologic ACTH, a slow-release formulation of corticotropin extracted from porcine pituitary glands (H.P. Acthar gel) will be effective in reducing proteinuria and improving lipid profile in patients with idiopathic MN.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01093157
Study type	Interventional
Source	University Health Network, Toronto
Contact
Status	Completed
Phase	Phase 1/Phase 2
Start date	February 2010
Completion date	February 2013

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT00001457` - Lamivudine for Chronic Hepatitis B	Phase 2
Recruiting	`NCT05505955` - Study of HRS-5965 in Healthy Subjects and Subjects With Renal Insufficiency	Phase 1
Recruiting	`NCT01240564` - The Nephrotic Syndrome Study Network (NEPTUNE)	N/A
Active, not recruiting	`NCT05174221` - A Study of Mezagitamab in Adults With Primary Immunoglobulin A Nephropathy Receiving Stable Background Therapy	Phase 1
Completed	`NCT00426348` - A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy	Phase 4
Recruiting	`NCT04662723` - Multicentre Clinical Study to Evaluate the Effect of Personalized Therapy on Patients With Immunoglobulin A Nephropathy.	Phase 4
Completed	`NCT02700516` - Recurrent Glomerulonephritis After Renal Transplantation	N/A
Recruiting	`NCT00862693` - Calcitriol in the Treatment of Immunoglobulin A Nephropathy	Phase 4
Completed	`NCT00983034` - The Effects of Helicobacter Pylori Eradication on Proteinuria in Patients With Membranous Nephropathy	N/A
Completed	`NCT00004990` - Once-A-Month Steroid Treatment for Patients With Focal Segmental Glomerulosclerosis	Phase 2
Recruiting	`NCT04846010` - Recovering Damaged Cells for Sequelae Caused by COVID-19, SARS-CoV-2	Phase 1/Phase 2
Terminated	`NCT04387448` - A Study of TRPC5 Channel Inhibitor in Patients With Diabetic Nephropathy, Focal Segmental Glomerulosclerosis, and Treatment-Resistant Minimal Change Disease	Phase 2
Terminated	`NCT04950114` - An Open-Label, Long-term Study of GFB-887 in Patients With Glomerular Kidney Diseases	Phase 2
Completed	`NCT00437463` - Treatment of Immunoglobulin A (IgA) Nephropathy by Angiotensin-Converting Enzyme (ACE) Inhibitor	Phase 3
Terminated	`NCT02523768` - Prevention in Recipients With Primary IgA Nephropathy of Recurrence After Kidney Transplantation: ATG-F Versus Basiliximab as Induction Immunosuppressive Treatment	Phase 4
Completed	`NCT00106561` - Using the Drug Spironolactone to Test If It Reduces Protein Leakage From the Kidney	Phase 2/Phase 3
Completed	`NCT04733040` - Efficacy, Safety and PK/PD of MOR202 in Anti-PLA2R + Membranous Nephropathy (aMN) (NewPLACE)	Phase 2
Completed	`NCT00001676` - Cyclophosphamide and Fludarabine to Treat Lupus Nephritis	Phase 1
Recruiting	`NCT02063100` - Efficacy and Safety of Shenyankangfu Tablets for Primary Glomerulonephritis	Phase 4
Completed	`NCT05283057` - Empagliflozin in Patients With Glomerulonephritis	Phase 3